descriptive
Analysis v1
20
0
Tesamorelin doesn't significantly change the fat under the skin in people with HIV-related body shape changes. This finding is from the abstract summary - full study details were not available
Scientific Claim
Tesamorelin use is associated with little effect on subcutaneous fat in HIV-1-infected patients with lipodystrophy.
Original Statement
“improve visceral fat adiposity with relatively little effect on subcutaneous fat”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract describes 'relatively little effect' but study design is unknown, so causal language should be replaced with 'associated with'.
Evidence from Studies
Supporting (1)
20
20
Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy
Case-Control Study
Human
2011 JanContradicting (0)
0
No contradicting evidence found